dc.contributor | Departament de Salut |
dc.contributor.author | Programa d'Harmonització Farmacoterapèutica |
dc.date.accessioned | 2021-06-22T09:49:01Z |
dc.date.available | 2021-06-22T09:49:01Z |
dc.date.issued | 2021-03-03 |
dc.identifier.citation | Programa d'Harmonització Farmacoterapèutica. Upadacitinib per al tractament de l’artritis reumatoide de moderada a greu. Barcelona: Servei Català de la Salut; 2021. |
dc.identifier.uri | https://hdl.handle.net/11351/6089 |
dc.description | Rheumatoid arthritis; Upadacitinib; JAK inhibitor |
dc.description.abstract | Rheumatoid arthritis (RA) is an inflammatory disease of autoimmune etiology characterized by chronic inflammation of the synovial membrane, which leads to the progressive destruction of joint structures. Typical symptoms include pain, swelling, joint stiffness, asthenia, malaise, fever, and weight loss, and tend to functionally limit the affected joints if left untreated. Extraarticular manifestations may appear, such as anorexia, subcutaneous nodules, serositis or vasculitis. |
dc.language.iso | cat |
dc.publisher | Servei Català de la Salut |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Artritis reumatoide - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Medicaments - Assaigs clínics |
dc.subject.mesh | Arthritis, Rheumatoid |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Evaluation |
dc.title | Upadacitinib per al tractament de l’artritis reumatoide de moderada a greu |
dc.type | info:eu-repo/semantics/report |
dc.subject.decs | artritis reumatoide |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | evaluación de medicamentos |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |